SCYNEXIS, Inc. Cash and Cash Equivalents
SCYNEXIS, Inc. (SCYX) had Cash and Cash Equivalents of $10.49 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $10.49M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $36.67M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $21.26M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $14.80M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $10.49M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $36.67M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $21.26M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $14.80M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $11.02M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $6.94M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $16.05M 10-K · filed 2026-03-04 |
| 2024-09-30 | $28.73M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $25.99M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $35.48M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $34.05M 10-K · filed 2025-03-12 |
| 2023-09-30 | $44.07M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $57.91M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $26.91M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $45.81M 10-K · filed 2024-03-28 |
| 2022-09-30 | $68.62M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $118.69M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $95.21M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $104.48M 10-K · filed 2023-03-31 |
| 2021-09-30 | $100.11M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $112.44M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $92.01M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $93.04M 10-K · filed 2022-03-29 |
| 2020-09-30 | $29.49M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $34.02M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $20.25M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $41.92M 10-K · filed 2021-03-29 |
| 2019-09-30 | $11.62M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $19.15M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $12.95M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $11.44M 10-K · filed 2020-03-11 |
| 2018-09-30 | $16.08M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $6.77M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $27.22M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $11.47M 10-K · filed 2019-03-14 |
| 2017-09-30 | $8.75M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $7.45M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $19.91M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $35.66M 10-K · filed 2018-03-13 |
| 2016-09-30 | $29.81M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $37.87M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $38.02M 10-Q · filed 2017-05-08 |
| 2015-12-31 | $46.98M 10-K · filed 2018-03-13 |
| 2015-09-30 | $53.77M 10-Q · filed 2016-11-07 |
| 2015-06-30 | $57.06M 10-Q · filed 2016-08-08 |
| 2015-03-31 | $27.62M 10-Q · filed 2016-05-09 |
| 2014-12-31 | $32.24M 10-K · filed 2017-03-13 |
| 2014-09-30 | $34.04M 10-Q · filed 2015-11-13 |
| 2014-06-30 | $38.42M 10-Q · filed 2015-08-19 |
| 2014-03-31 | $650.00K 8-K · filed 2015-10-30 |
| 2013-12-31 | $1.40M 10-K · filed 2017-03-13 |
| 2013-09-30 | $926.00K 10-Q · filed 2014-11-13 |
| 2013-06-30 | $860.00K 10-Q · filed 2014-08-13 |
| 2013-03-31 | $782.00K 10-Q/A · filed 2014-07-11 |
| 2012-12-31 | $2.38M 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |